Clinical trials: Generalized Anxiety Disorder
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals…
- Trial name
- NCT00674219
- Testing
- Memantine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Type 1 Diabetes Mellitus
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes…
- Trial name
- TN08 (NCT00529399)
- Testing
- GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
- Where
- 15 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Generalized Anxiety Disorder
Desensitization and Cognitive Therapy in General Anxiety.
This study will test the feasibility and safety of adding interpersonal and emotional processing techniques to standard cognitive behavioral therapy for generalized anxiety disorder.
- Trial name
- NCT00951340
- Testing
- Cognitive behavioral therapy (CBT), Emotional processing and interpersonal therapy, Listening therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Penn State University
Mental Disorder, General Population
Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)
France has been put on a lockdown for 8 weeks to prevent the spread of the COVID-19 virus between 17/03/2020 and 11/05/2020. During this lockdown, which is likely to have psychopathological repercussions on the population, the…
- Trial name
- DeathPercep (NCT04384419)
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Depression Disorders, Bipolar Affective Disorder
Epidemiological Study on the Prevalence of Mental Disorders in Slovakia
This study maps the current epidemiological situation of mental disorders in Slovakia. The aim of the study is to determine the prevalence of selected mental disorders in the adult population of the Slovak Republic, assess the…
- Conditions
- Depression Disorders, Bipolar Affective Disorder, Generalized Anxiety Disorder (GAD), Panic Disorder
- Trial name
- EpiMentDisSK (NCT07129408)
- Where
- Slovakia
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- Comenius University
Hoarding Disorder, Virtual Reality Based Therapy
Non-Immersive Virtual Environments for the Treatment of Hoarding Disorder
This experimental trial investigates whether Virtual Reality Exposure (VRe) helps individuals reduce the difficulty of discarding personal possessions. It will also evaluate the psychological state impacts of the intervention.
- Conditions
- Hoarding Disorder, Virtual Reality Based Therapy, General Population (no Specific Condition or Disease)
- Trial name
- HD&VR (NCT07160543)
- Testing
- Imagination Exposure, Non-immersive Virtual Reality Exposure
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Padova
Irritable Bowel Syndrome, Generalized Anxiety Disorder
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
The investigators propose to evaluate the effectiveness of duloxetine in treating subjects with both Irritable Bowel Syndrome (IBS) and Generalized Anxiety Disorder (GAD).
- Trial name
- NCT00961298
- Testing
- Duloxetine
- Volunteers
- 17 people
- Sponsor
- West Penn Allegheny Health System
Generalized Anxiety Disorder
Treatment of Patients With Anxiety Disorder (0777-022)
The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.
- Trial name
- NCT00539578
- Testing
- MK0777
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC